

# Kazunori Murai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5914494/publications.pdf>

Version: 2024-02-01

33  
papers

475  
citations

1163117

8  
h-index

940533

16  
g-index

33  
all docs

33  
docs citations

33  
times ranked

730  
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e902-e911.	4.6	30
2	Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 353-360.e1.	0.4	89
3	Rapid reduction in <i>BCR-ABL1</i> transcript predicts deep molecular response in dasatinib-treated chronic phase chronic myeloid leukaemia patients. <i>European Journal of Haematology</i> , 2018, 100, 27-35.	2.2	9
4	Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2018, 108, 510-515.	1.6	9
5	Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan. <i>Leukemia and Lymphoma</i> , 2017, 58, 1509-1511.	1.3	3
6	High prevalence of diffuse large B-cell lymphoma in occult hepatitis B virus-infected patients in the Tohoku district in Eastern Japan. <i>Journal of Medical Virology</i> , 2016, 88, 2206-2210.	5.0	12
7	Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization. <i>International Journal of Hematology</i> , 2016, 104, 344-357.	1.6	17
8	Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e528-e535.	4.6	261
9	A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia chronic phase patients with imatinib resistance or intolerance as evaluated using European Leukemia 2013 criteria. <i>European Journal of Haematology</i> , 2015, 95, 558-565.	2.2	2
10	Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes. <i>European Journal of Haematology</i> , 2014, 93, 290-296.	2.2	22
11	Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial. <i>Blood</i> , 2013, 122, 3998-3998.	1.4	2
12	Pharmacokinetic (PK) and Pharmacodynamic (PD) Study Of Dasatinib In Chronic Phase Of Newly Diagnosed Chronic Myeloid Leukemia (CML-CP). <i>Blood</i> , 2013, 122, 4031-4031.	1.4	0
13	Dasatinib Induced Thrombocytopenia Might Be Due To The Inhibition Of Proplatelet Formation Of Megakaryocytes Via The Pathways Including Rho/Rock and Rac. <i>Blood</i> , 2013, 122, 1071-1071.	1.4	0
14	Ponatinib Induced Thrombocytopenia Might Inhibit Proplatelet Formation of Megakaryocytes Via the Pathways Including Rho/Rock and Rac.. <i>Blood</i> , 2012, 120, 2186-2186.	1.4	0
15	Novel Concept of Platelet Production From Megakaryocyte in Intact Bone Marrow: Proplatelet and Thick Protrusion.. <i>Blood</i> , 2012, 120, 2300-2300.	1.4	1
16	Efficacy and Safety of Dasatinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance. <i>Blood</i> , 2011, 118, 4444-4444.	1.4	1
17	Hepatotoxicity During Eltrombopag Administration Might Be Due to Necrosis of Hepatocytes. <i>Blood</i> , 2011, 118, 2228-2228.	1.4	0
18	Safety, Feasibility and Efficacy of High Dose Ranimustine (MCNU), Carboplatin, Etoposide, and Cyclophosphamide (MCVC) Therapy Followed by Autologous Stem Cell Transplantation for Malignant Lymphoma.. <i>Blood</i> , 2010, 116, 4588-4588.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Bortezomib Induced Thrombocytopenia Might Be Due to the Inhibition of Proplatelet Formation of Megakaryocyte.. Blood, 2010, 116, 3696-3696.	1.4	0
20	Forming Cytoplasmic Fragment Is Implicated In the Final Step of Platelet Production. Blood, 2010, 116, 4793-4793.	1.4	0
21	Recombinant Human Erythropoietin Administration Decreases the Frequency of Excessive Apoptosis in Erythroid Progenitors in the Model Mouse of Anemia Due to Chronic Renal Failure.. Blood, 2007, 110, 3668-3668.	1.4	0
22	Decreased Megakaryocytopoiesis and No Excess of Platelet Destruction in Myelodysplastic Syndrome Patients.. Blood, 2007, 110, 4616-4616.	1.4	0
23	Mannose Labeled Liposome Containing DXR Administration Is Effective in Reversing Thrombocytopenia in the Model Mouse of Immune Thrombocytopenia.. Blood, 2007, 110, 2109-2109.	1.4	0
24	Mannose Labeled Liposome-Encapsulated Doxorubicin Is Effective in the Management of Experimental Immune Thrombocytopenic Purpura Model Mice.. Blood, 2006, 108, 3995-3995.	1.4	0
25	Thrombocytopoiesis Is Not Regulated by Thrombopoietin (TPO) but Proplatelet Formation (PPF) Stimulating Factor.. Blood, 2006, 108, 1112-1112.	1.4	0
26	Anemia of Chronic Renal Failure Is Associated with Much Higher Frequency of Apoptosis in Erythroid Progenitor in a Mouse Model.. Blood, 2006, 108, 1293-1293.	1.4	0
27	Danazol Stimulates Proplatelet Formation of Megakaryocytes Via Rac Activation Pathway.. Blood, 2005, 106, 4276-4276.	1.4	0
28	Ineffective Hematopoiesis in Megaloblastic Anemia Is Associated with Higher Frequency of Apoptosis in Each Lineage Immature and Mature Cells.. Blood, 2005, 106, 3601-3601.	1.4	0
29	Collagen Type I (CTI) Stimulates Proplatelet Formation (PPF) of Murine Megakaryocytes and Platelet like Particle Formation (PP) of Human Megakaryoblastic Cell Line (MEG) through the Activation of Rac.. Blood, 2005, 106, 4280-4280.	1.4	0
30	Myelodysplastic Syndrome with Bone Marrow Hypoplasia Is Associated with Much Higher Frequency of Apoptosis in CD 34+ Cells.. Blood, 2004, 104, 2370-2370.	1.4	1
31	TAT/HDL Induces the Phosphorylation of Cofilin in the Process of Platelet Production of Megakaryocytes.. Blood, 2004, 104, 2186-2186.	1.4	0
32	The Role of Rho/Rac Pathways in Proplatelet Formation of Megakaryocytes.. Blood, 2004, 104, 3890-3890.	1.4	0
33	A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage: A pilot study. Cancer, 1996, 78, 422-426.	4.1	14